February 10, 2022: Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement - 02/10/2022 | FDA n.d. https://www.fda.gov/advisory-committees/advisory-committee-calendar/february-10-2022-meeting-oncologic-drugs-advisory-committee-meeting-announcement-02102022 (accessed March 9, 2022).
- Yang Y.
- Wang Z.
- Fang J.
- Yu Q.
- Han B.
- Cang S.
- et al.
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerReferences
February 10, 2022: Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement - 02/10/2022 | FDA n.d. https://www.fda.gov/advisory-committees/advisory-committee-calendar/february-10-2022-meeting-oncologic-drugs-advisory-committee-meeting-announcement-02102022 (accessed March 9, 2022).
- Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (oncology pRogram by InnovENT anti-PD-1-11).J Thorac Oncol. 2020; 15: 1636-1646https://doi.org/10.1016/J.JTHO.2020.07.014/ATTACHMENT/A450760A-EEAF-4CFA-AC80-66972EBF946D/MMC3.PDF
- Importing oncology trials from China: a bridge over troubled waters?.Lancet Oncol. 2022; 23: 323-325https://doi.org/10.1016/S1470-2045(22)00071-7
National Medical Products Administration n.d. http://english.nmpa.gov.cn/(accessed March 9, 2022).
- Antibodies to watch in 2022.MAbs. 2022; 14https://doi.org/10.1080/19420862.2021.2014296/SUPPL_FILE/KMAB_A_2014296_SM6601.ZIP
- Comparison of cancer incidence between China and the USA.Cancer Biol Med. 2012; 9: 128https://doi.org/10.3969/J.ISSN.2095-3941.2012.02.009
Shanghai Junshi Biosciences Co., Ltd Press Release: Junshi Biosciences Announce Toripalimab Granted ODD in the US for EC n.d. https://www.junshipharma.com/en/News.html (accessed March 9, 2022).
FDA grants accelerated approval to zanubrutinib for mantle cell lymphoma | FDA n.d. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zanubrutinib-mantle-cell-lymphoma (accessed March 9, 2022).
- Simultaneous development of zanubrutinib in the USA and China.Nat Rev Clin Oncol. 2020; 17 (2020;17): 589-590https://doi.org/10.1038/s41571-020-0414-y
- Regulatory reliance to approve new medicinal products in Latin American and Caribbean countries.Rev Panam Salud Publica/Pan Am J Public Health. 2021; 45https://doi.org/10.26633/RPSP.2021.10
